The global anti-asthma drug market is expected to grow at a significant rate of 8.2% during the forecast period (2022-2028). Asthma is a chronic lung disease. It stimulates and constricts our airways, making it difficult to breathe. Asthma medications are used to treat breathing problems, among others. The growing prevalence of chronic diseases such as asthma, allergies and respiratory disorders with rising environmental pollution is a key factor driving market growth. Consumers are now getting aware of timely diagnosis and appropriate treatment of asthma which is causing another driving growth in the market.
(Get a 15% discount on the purchase of this report)
A full report of the global asthma drug market is available at: https://orionmarketreports.com/anti-asthma-drugs-market/94814/
According to the World Health Organization, more than 461,000 people died of asthma by 2020. To alleviate the global burden, the government and commercial health organizations have expanded their investments in developing new asthma treatments. for example-
In December 2021, Astrazenka Logic Controller is programmed in partnership with Amgan Inc. Developed by Tzeplomab, the first biologist to show statistically significant improvements at each central secondary endpoint compared to placebo in the Phase III trial, including lung function measurements and asthma control, was the first biologist to achieve a consistent and significant reduction in the adverse effects of severe asthma.
In September 2021, Avilion, a drug development company focused on co-development and funding drug candidates, announced high-level positive results from the trials in the mandala and third phase of Pat 027 (albuterol / bodsonid) in doses of 180/160 micrograms and 180/80 micrograms, and stood at all points The main end with significant benefits in asthma patients compared to individual components albutrol.
In October 2020, Snoopy revealed that their Phase 3 trial had received an encouraging response. Dupixant (dopilumab), according to the manufacturer, has reduced severe asthma attacks in children and is the only biological that has shown improvement in children’s lung function in a randomized phase 3 trial.
In September 2020, GalaxySmith Klein and Innovation, Inc., received approval from the U.S. Department of Health for the Trelliptical Elliptical to treat asthma patients age 18 and older. Tralage Elliptical is a single inhaler containing Pluticasone Foroate, Omeclidinium, and Willentrol (Pep / Omek / V). Omeclidinium is a long-acting muscarinic antagonist, willentrol is a long-acting beta-2-adrenergic agonist. Fluticasone Foroat is an inhaled steroid.
In April 2020, the company. Announced that a Phase 3 clinical endpoint trial for pluticasone propionate and salametrol (100/50 micrograms) inhalation powder has been successfully completed. The generic forms of Gasco’s Advice Discus include pluticasone propionate and 100/50 micrograms, 250/50 micrograms and 500/50 micrograms inhaled salamatrol powder.
In September 2019, Novartis announced that a Phase C iridium study on the inhaled combination 149 among people with uncontrolled asthma yielded good findings. This asthma treatment candidate allows patients to better regulate their asthma symptoms, resulting in a higher improvement in lung function.
Market coverage
Available market number for 2021-2028
Base year -2021
Forecast period-2022-2028
Covered section-
By type
By application
Covered areas-
North America
Europe
Asia Pacific
the rest of the world
* Competitive landscape care – perception, including. GalaxySmiteCline., Novartis International a. G., Sanofi S.. A., Regeneron Pharmaceuticals, Inc., and others.
Key questions discussed in the report
What is the growth rate of the market?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has Cubid-19 affected the market?
Deviation from the forecast before Covid 19
The region and sector most affected
Who is the market leader?
How do players face challenges to sustain growth?
Where is the investment opportunity?
Global Asthma Drug Market Report by Sectors
By type
Long-term control drugs
Rapid Relief Medications (Rescue Medications)
Drugs for asthma caused by allergies
By application
Hospital pharmacy
Retail pharmacy
Online pharmacy
About us:
Orion Market Reports strives to provide an exclusive combination of quality and quantitative market research reports to clients around the world. Our organization helps multinational and local organizations alike to strengthen their businesses by providing in-depth market insights and the most credible future market trends. Our reports cover all major aspects of markets that provide insights and market outlook to global customers.
Media contact:
Company Name: Orion Market Reports
Contact: Mr. Anurag Tiwari
Email: [email protected]
Contact No: + 91 780-304-0404